Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study.

Christos SachpekidisAnnette Kopp-SchneiderJessica C HasselAntonia Dimitrakopoulou-Strauss

Published in: EJNMMI research (2021)

PET/CT, performed already after administration of two ICIs' cycles, can identify the majority of non-responders in melanoma immunotherapy. In order to tackle however, the non-negligible phenomenon of pseudoprogression, another follow-up PET/CT, the usage of novel response criteria and vigilance over emergence of radiological irAEs are recommended. Moreover, the investigation of spleen glucose metabolism may offer further prognostic information in melanoma patients under ICIs.

Keyphrases

pet ct
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
positron emission tomography
healthcare
computed tomography
social media
patient reported
skin cancer
health information